Together, the vaccine program may enhance antigen presentation and myeloid polarization (↑CD86/CD163), followed by Th1/Th17-skewed adaptive responses (↑IFN-γ, ↑IL-17), B-cell activation/anti–PD-L1 antibodies, and CD8+ CTL cytotoxicity, consistent with tumor control. The gene discussed is CD274; the disease is neoplasm.